Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

etion of the healthy volunteer study, Anadys plans to transition rapidly to a short-term Phase Ib study of ANA598 in HCV-infected patients by early fourth quarter.

-- Acceleration of ANA598 Development Activities. In late April, Anadys announced the acceleration of certain non-clinical activities for ANA598 into 2008 in order to enable a more rapid advancement into Phase II trials in 2009. The decision to accelerate the non-clinical development activities for ANA598 was based on promising results from the preclinical evaluation of ANA598.

-- Additional Mechanism in Hepatitis C Development. In early July, Anadys announced the expansion of its development efforts in HCV to include clinical investigation of ANA773, its oral Toll-Like Receptor 7 (TLR7) agonist. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and potentially complementary to, ANA598. Results of recently completed 13-week GLP toxicology studies have shown that with every-other-day dosing of ANA773, immune stimulation of a magnitude believed to confer therapeutic potential can be achieved without adverse toxicology findings.

-- Initiation of Phase I Clinical Trial of ANA773 in HCV. Following the Company's announcement of its plans to study ANA773 in HCV, dosing in healthy volunteers has commenced in Part A of the ANA773 HCV Phase I clinical trial. The primary objectives of Part A of the study are to assess safety and tolerability. Part B of the study, which will explore every-other-day dosing over 28 days in HCV-infected patients, is expected to begin early in the fourth quarter. The primary objectives of Part B are to assess safety, tolerability and viral load decline.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I Clinical Trial of ANA773 in oncology. The Company expects to identify a pharmacologically active dose and establish the profile of immune stimulation by year-end, which will supp
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Investor-Edge has ... Ltd (NASDAQ: GENE ), Agilent Technologies Inc. ... (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... ). Free research report on Genetic Technologies can ... April 30, 2015, the NASDAQ Composite ended at ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Deutsche Bank 40 ... Massachusetts . The presentation will take place ... and can be accessed via a live webcast on the ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and oligonucleotide ... capability to serve biotechnology pharmaceutical clients. A commitment ... to drive Nitto Avecia to enhance synthesis scale ... , In Fall 2014, Nitto Avecia first demonstrated ... Milford, MA facility, which is recognized as a ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... , , NEW ... announces that a new market research report is ... Future of Nutrigenomics: New opportunities in personalized nutrition ... , Nutrigenomics explores how nutrients or bioactive ...
... , ROCKVILLE, Md. , Feb. 16 ... focused on the development and commercialization of clinical-stage products for central ... fourth quarter and full year ended December 31, 2009 . ... for the fourth quarter of 2009, compared to $7.7 ...
... ... partnering with sponsors and CROs , ... Orlando, FL (PRWEB) February 16, 2010 -- Akaza Research is pleased ... 12-14 in Orlando, Florida. The event is being held at the Orlando World Center ...
Cached Biology Technology:Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 11Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 12Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 13Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 14Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 15Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 16Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 17Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 18Akaza Research to Present OpenClinica Electronic Data Capture Software at Partnerships in Clinical Trials 2010 2
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... genetic clues into rheumatoid arthritis (RA), a chronic inflammatory ... yet known, RA has been linked to an inherited ... occurrence among siblings seems to be random. ... profiles in patients with RA, researchers at the University ...
... a new low-cost system that analyzes scattered laser light ... processing and homeland security at one-tenth the cost of ... Using Optical Scattering Technology - works by shining a ... in a nutrient medium. , "Unlike conventional methods, we ...
... vegetables, the other infecting humans - essentially use the ... the cells of their respective hosts. , That's what ... a study published in the current issue of the ... that the pathogen that causes malaria in humans and ...
Cached Biology News:New genes implicated in rheumatoid arthritis 2Purdue creates new low-cost system to detect bacteria 2Purdue creates new low-cost system to detect bacteria 3Purdue creates new low-cost system to detect bacteria 4Malaria, potato famine pathogen share surprising trait 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
...
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: